J&J Finishes Tough Year With Optimism For 2021
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
You may also be interested in...
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
The resurgence of the pandemic during the fourth quarter of 2020 led to slowdown in elective procedures, negatively impacting sales of the four big ortho players.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.